Clerio Vision

Clerio Vision is a private, pre-revenue medical device innovator leveraging its proprietary LIRIC (Laser Induced Refractive Index Change) platform to address multiple multi-billion-dollar ophthalmic markets. The technology, born from University of Rochester research, uses femtosecond lasers to 'write' corrective optics inside materials, enabling novel, non-invasive solutions for presbyopia, myopia progression, post-cataract optimization, and refractive surgery. With $80M in R&D investment, a strong IP portfolio, and completed first-in-human trials, Clerio is positioned to disrupt traditional vision correction paradigms if it can successfully navigate clinical development, regulatory pathways, and market adoption.

LIRIC® (Laser Induced Refractive Index Change) – a femtosecond laser platform that non-invasively alters the refractive index of transparent materials (e.g., hydrogel lenses, corneal tissue) to create corrective optics without cutting or removing material.

Clerio faces competition from dominant multinationals (Alcon, J&J Vision, Bausch + Lomb) in lenses and surgical devices, and from established refractive surgery providers. Its key differentiator is the non-invasive, material-sparing nature of LIRIC, which may offer safety and efficacy advantages, but it must prove these in head-to-head competition with mature, lower-cost technologies.